PFF

Bintai Kinden Expands Further into O&G

Retrieved on: 
Tuesday, January 3, 2023

Executive Director of Bintai Kinden, En.

Key Points: 
  • Executive Director of Bintai Kinden, En.
  • PFF is a supplier of pipes, flanges, fittings, valves and other O&G-related equipment.
  • Azri Azerai, Executive Director of Bintai Kinden said, "The latest award of subcontracts to BESB is part of the partnerships and tie-ups we are pursuing to grow our O&G-related business.
  • This includes seeking opportunities and partnerships with companies that share the same vision as Bintai Kinden, in Southeast Asia.

7 Medical Centers Join Pulmonary Fibrosis Foundation's Care Center Network

Retrieved on: 
Wednesday, December 7, 2022

CHICAGO, Dec. 7, 2022 /PRNewswire/ -- More than 250,000 Americans living with pulmonary fibrosis now have access to expert treatment at seven medical centers that have been added to the Pulmonary Fibrosis Foundation's (PFF) Care Center Network (CCN). With the new sites, the PFF Care Center Network totals 81 medical facilities in 35 states across the U.S.

Key Points: 
  • CHICAGO, Dec. 7, 2022 /PRNewswire/ -- More than 250,000 Americans living with pulmonary fibrosis now have access to expert treatment at seven medical centers that have been added to the Pulmonary Fibrosis Foundation's (PFF) Care Center Network (CCN).
  • This year we resumed our expansion plans and added a total of 13 leading pulmonology centers to our network."
  • The newest medical centers to receive the Care Center Network designation are:
    Corewell Health East (Royal Oak, Mich.) Coordinator: Heather Whitt, RN
    Loma Linda University (Loma Linda, Calif.) Coordinator: Jeanette Merrill-Henry
    University of California San Diego (San Diego, Calif.) Coordinator: Nadine Basbas
    University of Nebraska Medical Center (Omaha, Neb.)
  • The 81 sites now operating in the PFF Care Center Network are:

Nitrase Therapeutics Presented Data on the Importance of Synuclein Nitrase on the Synaptic Activity of Differentiated Dopaminergic Neurons at the Society for Neuroscience (SFN) Conference

Retrieved on: 
Monday, November 14, 2022

BRISBANE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- Nitrase Therapeutics, Inc., a biopharmaceutical company deploying its NITROME platform to build a pipeline of therapies targeting nitrases, a new class of enzymes discovered in-house that are involved in a broad variety of diseases, today announced the company presented the poster titled “Synuclein Nitrase, a Novel Enzyme that Catalyzes Nitration of Synuclein, Modulates Dopaminergic Neuron Activity” (abstract #110.04 / B29) at the Society for Neuroscience 2022 (SFN) conference held from November 12-16, 2022 in San Diego, CA.

Key Points: 
  • In preclinical studies, Nitrase examined the effect of knocking out Synuclein Nitrase on the survival, growth and electrical activity of differentiated dopaminergic neurons (iDAs) derived from human iPSC lines from both non-PD and familial PD (fPD) patients.
  • Knocking out Synuclein Nitrase also reduced synuclein accumulation in the insoluble fraction of preformed fibril (PFF) treated iDAs.
  • These studies establish that reducing Synuclein Nitrase levels can reduce electrophysiological deficits and insolubility of synuclein in PD iDA neurons.
  • These data demonstrate that targeting Synuclein Nitrase could serve as a novel disease-modifying therapeutic for patients with Parkinsons disease.

Piaggio Fast Forward Introduces New Business Solutions for More Productive, Efficient and Safer Work Environments

Retrieved on: 
Monday, November 14, 2022

BOSTON, Nov. 14, 2022 /PRNewswire/ -- Piaggio Fast Forward (PFF), a leader in smart following technology and subsidiary of the Piaggio Group (PIA.MI), announced today that the company will be offering business customers a better way to manage the human-robot relationship and maximize the power of their data. Beginning in early 2023, PFF will offer PFF pro™ tools fleet management software to enable and enhance the next-generation of the dedicated business version of our products: the PFF pro gitamini™ and pro gitaplus™ robots. The cloud-based tool is a next-generation fleet management solution purpose-built to optimize and augment the working relationship between humans and their robotic counterparts. This proprietary software provides integration and orchestration features allowing teams to achieve more while collaborating with their robot partners. The software is highly visual and intuitive and begins driving value from day one via integrations and reporting functionality. It is an out-of-the-box technology solution to drive immediate value to businesses via enhanced worker safety, increased efficiencies and improved client experiences in select industries including travel, hospitality, real estate, retail, business construction and more.

Key Points: 
  • This proprietary software provides integration and orchestration features allowing teams to achieve more while collaborating with their robot partners.
  • The software is highly visual and intuitive and begins driving value from day one via integrations and reporting functionality.
  • Assigning robots to tasks and the people completing those tasks throughout each business day is now a couple of simple clicks away.
  • Smart following technology leader Piaggio Fast Forward (PFF) is a Boston-based company founded in 2015 and funded by the Piaggio Group, the Italian manufacturer and creator of the iconic Vespa scooter.

Pulmonary Fibrosis Foundation Expands Research Into Devastating Lung Disease

Retrieved on: 
Tuesday, November 1, 2022

Dr. Gillian Goobie(PFF Scholar Class of 2020), University of Pittsburgh, studies the role that air pollution plays in the development and progression of interstitial lung diseases.

Key Points: 
  • Dr. Gillian Goobie(PFF Scholar Class of 2020), University of Pittsburgh, studies the role that air pollution plays in the development and progression of interstitial lung diseases.
  • Her paper, Association of Particulate Matter Exposure With Lung Function and Mortality Among Patients With Fibrotic Interstitial Lung Disease , was published in the Journal of the American Medical Association Internal Medicine on Oct. 17, 2022.
  • Dr. Jeremy Katzen(PFF Scholar Class of 2019), University of Pennsylvania, received a National Institutes of Health K08 award.
  • Dr. Katzen's research focuses on understanding the impairment process ofalveolar type-2 (AT2) cells, which are important cellular components of normal lung function and repair, and how that may contribute to the initiation and progression of lung fibrosis
    The mission of the Pulmonary Fibrosis Foundation is to accelerate the development of new treatments and ultimately a cure for pulmonary fibrosis.

Piaggio Fast Forward™ Launches a Chic Personal Robot for Holiday 2022: Introducing the Exclusive "gitamini™ limited edition" Where High Tech Meets High Fashion and Healthy Living

Retrieved on: 
Tuesday, October 25, 2022

A leader in following technology, PFF continues to revolutionize the way humans and machines interact by designing innovative mobile tech solutions that move the way people move—to help people walk more, walk farther, and to allow them to do more of their everyday living on foot. PFF continues to listen to customer feedback and expand its family of first-of-their--kind following robots programmed with pedestrian etiquette. 

Key Points: 
  • This first all-black limited edition of gitamini is the perfect gift for healthy living enthusiasts, fashion and accessories lovers, environmentally conscious individuals, tech adopters, and those with pedestrian-first lifestyles.
  • PFF's first limited edition all-black colorway is timeless and elevated, making it the perfect accessory to take you through the holiday season and beyond.
  • With most walking trips being a mile or less, gitamini makes those 2,000 steps easier, more fun and now eye-catching.
  • "This holiday was the perfect opportunity to create an exclusive colorway for the best selling gitamini robot.

NextGen Prospect Has Launched a Strategic Partnership With PFF

Retrieved on: 
Friday, September 30, 2022

"We've seen PFF's team product first hand through our work with the Reese's Senior Bowl," saidMarc Vitticore, Founder of NextGen Prospect.

Key Points: 
  • "We've seen PFF's team product first hand through our work with the Reese's Senior Bowl," saidMarc Vitticore, Founder of NextGen Prospect.
  • NextGen Prospect has infused PFF Ultimate data into its existing Roster Builder, Advanced Scouting, Transfer Portal, custom features and more.
  • "The integration of PFF data will allow NextGen Prospect to quickly provide critical data that staffs across the country are utilizing every day," said Rick Drummond, GM of Football at PFF.
  • Headquartered in Fairport, NY, NextGen Prospect was launched in 2020 and has quickly built a client base of major college football and professional football teams.

NextGen Prospect Launches Strategic Partnership With PFF

Retrieved on: 
Thursday, September 29, 2022

"We've seen PFF's team product first hand through our work with the Reese's Senior Bowl," saidMarc Vitticore, Founder of NextGen Prospect.

Key Points: 
  • "We've seen PFF's team product first hand through our work with the Reese's Senior Bowl," saidMarc Vitticore, Founder of NextGen Prospect.
  • NextGen Prospect has infused PFF Ultimate data into its existing Roster Builder, Advanced Scouting, Transfer Portal, custom features and more.
  • "The integration of PFF data will allow NextGen Prospect to quickly provide critical data that staffs across the country are utilizing every day," said Rick Drummond, GM of Football at PFF.
  • Built on collaboration and innovation, NextGen Prospect engineers powerful solutions for teams to manage their evolving roster needs.

Ethos Asset Management Inc., USA, Announces Deal with Gligan Fitness Ltd., UK, Under a Philanthropic Financing Facility (PFF) to Improve the Lives of Less Privileged Children in the United Kingdom

Retrieved on: 
Wednesday, September 28, 2022

SAN DIEGO, Sept. 28, 2022 /PRNewswire/ -- ETHOS ASSET MANAGEMENT INC USA, announced a new long-term financing partnership with Gligan Fitness Ltd., United Kingdom. Gligan Fitness promotes equality and self-reliance by providing support to allow young people to become agents of their development and progress. Ethos has committed to providing significant capital infusion that will continue for several years.

Key Points: 
  • SAN DIEGO, Sept. 28, 2022 /PRNewswire/ -- ETHOS ASSET MANAGEMENT INC USA , announced a newlong-term financing partnership with Gligan Fitness Ltd., United Kingdom.
  • Gligan Fitness promotes equality and self-reliance by providing support to allow young people to become agents of their development and progress.
  • "We are thrilled and honored to be partnering with Gligan Fitness under the dynamic and passionate leadership of CEO and Founder, Laura Gligan.
  • Gligan Fitness Ltd (Gligan Fitness) is an independent UK based company working to improve physical and mental wellbeing in our communities.

Gain Therapeutics Presents New Preclinical Data Demonstrating Potential Disease Modifying Benefits of its Novel Brain Penetrant Small Molecule Candidate GT-02287 in Two Preclinical Models of Parkinson’s Disease

Retrieved on: 
Monday, September 19, 2022

BETHESDA, Md., Sept. 19, 2022 (GLOBE NEWSWIRE) -- Gain Therapeutics, Inc. (Nasdaq: GANX) (“Gain”, or the “Company”), a biotechnology company transforming drug discovery with its proprietary computational drug discovery platform identifying novel allosteric binding sites and creating small molecule treatments, today announced the presentation of new preclinical data at the International Congress of Parkinson’s Disease and Movement Disorders 2022 Annual Meeting in Madrid, Spain, evaluating the neuroprotective effect of Gain’s lead ‘Structurally Targeted Allosteric Regulator’ (STAR) compound, GT-02287, in preclinical in vitro and in vivo models of Parkinson’s disease.

Key Points: 
  • We are especially excited by these latest data which expand on the accumulating preclinical evidence supporting the potential disease-modifying properties of our novel small molecule candidate, GT-02287, said Joanne Taylor, Ph.D., Senior Vice President of Research at Gain Therapeutics.
  • If these results are supported in future clinical studies, GT-02287 could become an important first-in-class disease-modifying therapy for Parkinsons disease.
  • In the first study, the ability of GT-02287 to neutralize CBE-mediated neurodegeneration was evaluated in rat mesencephalic neurons.
  • Mutations in the GBA1 gene, encoding the lysosomal enzyme GCase, represents the most common genetic risk factor for Parkinsons disease (PD).